-
Masitinib Slows Progression in PPMS and Non-active SPMS, Trial Reports
Masitinib, a daily oral therapy of the innate immune system by AB Science, was seen to slow disability progression in 200 patients at trial’s lower dose. Read more here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.